Search results for " Basic"

showing 10 items of 10515 documents

Candida spp. Determination and Th1/Th2 Mixed Cytokine Profile in Oral Samples From HIV+ Patients With Chronic Periodontitis

2019

Background: Chronic periodontitis (CP), caused by bacteria and fungi, appears in up to 66% of HIV-patients. The impact and association of HIV-treatment (HAART) and Candida itself has not been properly evaluated in the development and progression of CP. The immunopathogenesis is characterized by CD4+ T-cells activation and the balance between the T-helper 1 (Th1) and T-helper 2 (Th2) or a mixed cytokine profile. Currently, the associated causes of an immune response in HIV-patients with CP is controversial. Our aims were the determination of Candida spp. and cytokine profile in oral samples from HIV-positive patients with CP, considering the CD4+ T cells levels and HAART use.Methods: From 50…

lcsh:Immunologic diseases. Allergy0301 basic medicineSalivaHAARTmedicine.medical_treatmentImmunologyGroup AGroup BMicrobiology03 medical and health sciences0302 clinical medicinemedicineImmunology and AllergyOriginal ResearchCandida sppmedicine.diagnostic_testbusiness.industryHIVchronic periodontitisImmunosuppressionmedicine.diseaseChronic periodontitiscytokinesCorpus albicans030104 developmental biologyCytokineImmunoassaylcsh:RC581-607business030215 immunologyFrontiers in Immunology
researchProduct

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.

2018

International audience; NKp46 (CD335) is a surface receptor shared by both human and mouse natural killer (NK) cells and innate lymphoid cells (ILCs) that transduces activating signals necessary to eliminate virus-infected cells and tumors. Here, we describe a spontaneous point mutation of cysteine to arginine (C14R) in the signal peptide of the NKp46 protein in congenic Ly5.1 mice and the newly generated NCR(B6C14R) strain. Ly5.1(C14R) NK cells expressed similar levels of Ncr1 mRNA as C57BL/6, but showed impaired surface NKp46 and reduced ability to control melanoma tumors in vivo. Expression of the mutant NKp46(C14R) in 293T cells showed that NKp46 protein trafficking to the cell surface …

lcsh:Immunologic diseases. Allergy0301 basic medicineSignal peptideintracellular traffickingImmunologyCellCongenicinnate lymphoid cellsBiologymedicine.disease_causelcsh:RC254-28203 medical and health sciences0302 clinical medicinemedicineImmunology and Allergyddc:610congenic miceReceptorOriginal ResearchMutationEndoplasmic reticulumInnate lymphoid cellHEK 293 cellslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCell biology030104 developmental biologymedicine.anatomical_structureOncologyactivation receptors[SDV.IMM]Life Sciences [q-bio]/Immunologylcsh:RC581-607030215 immunology
researchProduct

RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?

2019

Susceptibility to ankylosing spondylitis (AS) is polygenic with more than 100 genes identified to date. These include HLA-B27 and the aminopeptidases (ERAP1, ERAP2, and LNPEPS), which are involved in antigen processing and presentation to T-cells, and several genes (IL23R, IL6R, STAT3, JAK2, IL1R1/2, IL12B, and IL7R) involved in IL23 driven pathways of inflammation. AS is also strongly associated with polymorphisms in two transcription factors, RUNX3 and T-bet (encoded by TBX21), which are important in T-cell development and function. The influence of these genes on the pathogenesis of AS and their potential for identifying drug targets is discussed here.

lcsh:Immunologic diseases. Allergy0301 basic medicineTBX21Mini ReviewImmunologyBiologyCD8-Positive T-Lymphocytesmedicine.disease_causeAminopeptidasesInterleukin-23Polymorphism Single NucleotideAutoimmunity03 medical and health sciences0302 clinical medicineankylosing spondylitisInterleukin 23medicineImmunology and AllergyHumansImmunologic FactorsSpondylitis AnkylosingMolecular Targeted TherapyInterleukin-7 receptorTranscription factorHLA-B27 AntigenAnkylosing spondylitistherapyAntigen processingautoimmunityReceptors Interleukinmedicine.disease3. Good healthKiller Cells Natural030104 developmental biologyCore Binding Factor Alpha 3 SubunitGene Expression RegulationinflammationImmunologylcsh:RC581-607T-Box Domain ProteinsFunctional genomicsfunctional genomics030215 immunologyFrontiers in Immunology
researchProduct

Mycobacterium tuberculosis Drives Expansion of Low-Density Neutrophils Equipped With Regulatory Activities

2019

In human tuberculosis (TB) neutrophils represent the most commonly infected phagocyte but their role in protection and pathology is highly contradictory. Moreover, a subset of low-density neutrophils (LDNs) has been identified in TB, but their functions remain unclear. Here, we have analyzed total neutrophils and their low-density and normal-density (NDNs) subsets in patients with active TB disease, in terms of frequency, phenotype, functional features, and gene expression signature. Full-blood counts from Healthy Donors (H.D.), Latent TB infected, active TB, and cured TB patients were performed. Frequency, phenotype, burst activity, and suppressor T cell activity of the two different subse…

lcsh:Immunologic diseases. Allergy0301 basic medicineTuberculosisPhagocyteLymphocytePhagocytosisT cellImmunologytranscriptomic analysiPeripheral blood mononuclear cellMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineneutrophilsmedicineImmunology and Allergylow density neutrophiltranscriptomic analysisOriginal Researchbiologylow density neutrophilsphagocytosisneutrophilphagocytosibiology.organism_classificationmedicine.disease3. Good healthRespiratory burst030104 developmental biologymedicine.anatomical_structuretuberculosisImmunologylcsh:RC581-607030215 immunology
researchProduct

Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer ste…

2018

Despite marked advancements in its treatment, breast cancer is still the second leading cause of cancer death in women, due to relapses and distal metastases. Breast cancer stem cells (CSCs), are a cellular reservoir for recurrence, metastatic evolution and disease progression, making the development of novel therapeutics that target CSCs, and thereby inhibit metastases, an urgent need. We have previously demonstrated that the cystine-glutamate antiporter xCT (SLC7A11), a protein that was shown to be overexpressed in mammary CSCs and that plays a key role in the maintenance of their redox balance, self-renewal and resistance to chemotherapy, is a potential target for mammary cancer immunoth…

lcsh:Immunologic diseases. Allergy0301 basic medicinecancer stem cellmedicine.medical_treatmentImmunologylcsh:RC254-28203 medical and health sciences0302 clinical medicineBreast cancerCancer immunotherapyCancer stem cellbovine herpesvirus 4-based vector; cancer stem cell; immunotherapy; Mammary cancer; xCT; Immunology and Allergy; Immunology; OncologymedicineImmunology and Allergybovine herpesvirus 4-based vectorOriginal ResearchAntibody-dependent cell-mediated cytotoxicitybusiness.industryxCTCancerImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMetastatic breast cancer030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchMammary cancerimmunotherapyStem celllcsh:RC581-607businessOncoImmunology
researchProduct

Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatment

2018

The profound but frequently transient clinical responses to BRAFV600 inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance therapeutic responses. However, to which extent BRAFV600 inhibition may affect melanoma immunogenicity over time remains largely unknown. To support the development of an optimal treatment protocol, we studied the impact of prolonged BRAFi exposure on the recognition of melanoma cells by T cells in different patient models. We demonstrate that autologous CD8+ tumor-infiltrating lymphocytes (TILs) efficiently recognized short-term (3, 7 days) BRAF…

lcsh:Immunologic diseases. Allergy0301 basic medicinecd8+ t cellsmedicine.medical_treatmentT cellImmunologyMedizinlcsh:RC254-282mekresistance03 medical and health sciences0302 clinical medicineAntigenantigensmelanomaImmunology and AllergyMedicineCytotoxic T cellbusiness.industryMelanomaImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseTumor antigeninhibitor030104 developmental biologymedicine.anatomical_structureOncologyCSPG4030220 oncology & carcinogenesisCancer researchlcsh:RC581-607businessbrafCD8
researchProduct

Autoantigens in the trabecular meshwork and glaucoma‐specific alterations in the natural autoantibody repertoire

2019

Abstract Objectives Primary open‐angle glaucoma (POAG) is a neurodegenerative disorder leading to a gradual vision loss caused by progressive damage to the optic nerve. Immunological processes are proposed to be involved in POAG pathogenesis. Altered serological autoantibody levels have been frequently reported, but complete analyses of the natural autoantibodies with respect to disease‐related alterations are scarce. Here, we provide an explorative analysis of pathways and biological processes that may involve naturally immunogenic proteins and highlight POAG‐specific alterations. Methods Mass spectrometry‐based antibody‐mediated identification of autoantigens (MS‐AMIDA) was carried out in…

lcsh:Immunologic diseases. Allergy0301 basic medicinegenetic structuresImmunologyGlaucomaPDGFRBBiologymedicine.disease_causeAutoimmunityPathogenesis03 medical and health sciences0302 clinical medicineAntigenmedicineImmunology and AllergyGeneral Nursingtrabecular meshworkAutoantibodymedicine.diseaseimmunoproteomicsautoantigeneye diseasesglaucoma030104 developmental biologymedicine.anatomical_structureImmunologybiomarkerBiomarker (medicine)Original Articlenatural autoantibodiessense organsTrabecular meshworklcsh:RC581-607030217 neurology & neurosurgeryClinical & Translational Immunology
researchProduct

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

2018

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to improve with the incorporation of this new class of agents with current MM therapies. However, both antigens are also expressed on other normal tissues including hematopoietic lineages and immune effector cells, which may limit their long-term clinical use. B cell maturation antigen (BCMA), a transmembrane glycoprotein in the tumor necrosis factor receptor superfamily 17 (TNFRSF17), is expressed a…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.drug_classT-Lymphocytesmedicine.medical_treatmentImmunologyReceptors Antigen T-CellT-Cell Antigen Receptor Specificitymonoclonal antibody drug conjugateReviewAntibodies Monoclonal HumanizedMonoclonal antibodyImmunotherapy Adoptivebi-specific antibody03 medical and health sciences0302 clinical medicineAntigenSignaling Lymphocytic Activation Molecule FamilyAntibodies BispecificmedicineAnimalsHumansImmunology and AllergyElotuzumabbusiness.industrySLAMF7B-Cell Maturation AntigenAntibodies MonoclonalImmunotherapychimeric antigen receptor T cellADP-ribosyl Cyclase 1Chimeric antigen receptormultiple myelomaB-cell maturation antigen030104 developmental biologymonoclonal antibody030220 oncology & carcinogenesisProteasome inhibitorCancer researchImmunotherapytargeted immunotherapylcsh:RC581-607businessmedicine.drugFrontiers in Immunology
researchProduct

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refract…

2018

ABSTRACT We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-escalation study with six different dosing schedules. The primary endpoint was frequency and severity of adverse events (AEs). Secondary endpoints included pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. Sixty-five patients received solitomab at doses between 1 and 96 µg/day for ≥28 days. Fifteen patients had dose-limiting toxicities (DLTs): e…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.medical_specialtyImmunologyAMG 110bispecificlcsh:RC254-282Gastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSolitomabRefractoryPharmacokineticsInternal medicineImmunology and AllergyMedicineAdverse effectOriginal Researchbusiness.industryEpCAM phase 1Epithelial cell adhesion moleculesolitomablcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBiTE®CD3Discontinuation030104 developmental biologyMT110OncologyTolerabilitychemistry030220 oncology & carcinogenesisPharmacodynamicssolid tumorimmunotherapylcsh:RC581-607businessOncoimmunology
researchProduct

Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.

2018

Immune checkpoint blockade (ICB) is currently evaluated in patients with glioblastoma (GBM), based on encouraging clinical data in other cancers, and results from studies with the methylcholanthrene-induced GL261 mouse glioma. In this paper, we describe a novel model faithfully recapitulating some key human GBM characteristics, including low mutational load, a factor reported as a prognostic indicator of ICB response. Consistent with this observation, SB28 is completely resistant to ICB, contrasting with treatment sensitivity of the more highly mutated GL261. Moreover, SB28 shows features of a poorly immunogenic tumor, with low MHC-I expression and modest CD8(+) T-cell infiltration, suggest…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.medical_treatmentGL261ImmunologyOncology and CarcinogenesisMajor histocompatibility complexMalignancylcsh:RC254-282Mutational loadVaccine Related03 medical and health sciences0302 clinical medicineRare DiseasesGliomamedicineImmunology and Allergyddc:576.5sb28mutational loadCancerddc:616biologybusiness.industryBrief ReportSB28glioblastomaNeurosciencesImmunotherapyimmune checkpoint blockadelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmune checkpointBlockadeBrain DisordersBrain Cancer030104 developmental biologyOncologygl261030220 oncology & carcinogenesisCancer researchbiology.proteinImmunizationlcsh:RC581-607businessGlioblastomaCD8Immune checkpoint blockadeGlioblastoma
researchProduct